EW240816P95000
- 35.50
- +0.80+2.31%
Edwards Lifesciences Newsroom
Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $90
Edwards Lifesciences Price Target Cut to $91.00/Share From $107.00 by Goldman Sachs
Edwards Lifesciences Analyst Ratings
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $90
Barclays Keeps Their Buy Rating on Edwards Lifesciences (EW)
Hold Rating on Edwards Lifesciences Amid TAVR Challenges and Competitive Pressures
Edwards Lifesciences Price Target Cut to $70.00/Share From $100.00 by TD Cowen
Edwards Lifesciences Downgraded at JPM, Truist on Slower Transcatheter Valve Growth
Oppenheimer Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $90
UBS Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $90
Oppenheimer Adjusts Price Target on Edwards Lifesciences to $90 From $100
Edwards Lifesciences Price Target Cut to $70.00/Share From $102.00 by Baird
Analysts Offer Insights on Healthcare Companies: Natera (NTRA) and Edwards Lifesciences (EW)
Edwards Lifesciences: Hold Rating Amidst TAVR Slowdown and Operational Challenges
RBC Capital Keeps Their Buy Rating on Edwards Lifesciences (EW)
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $90
Analysts' Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (EW), Molina Healthcare (MOH) and Community Health (CYH)
Edwards Lifesciences Analyst Ratings
TD Cowen Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
Edwards Lifesciences: A Strategic Hold Amid Expansion and Anticipated Clinical Trials